Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intercept Retakes The Lead In NASH

Executive Summary

A week after Gilead missed its primary endpoint in the first Phase III NASH trial, Intercept shows a statistically significant fibrosis benefit in Phase III with OCA. It plans to file for approval later this year.

Advertisement

Related Content

IPO Update: Gottlieb’s Resignation Pulls Down Five Of Eight Newly Public Biopharmas
In NASH, Gilead Swung For The Fences And Struck Out Again
Genfit May Be Gaining An Edge In NASH Race
Intercept's Revised NASH Trial Improves Prospects
Genfit Says Safety/Tolerability Will Give Elafibranor An Edge In NASH
'Clean Label' For Intercept's Ocaliva In PBC Bodes Well For NASH Claim
Intercept Thinks Fibrosis Effect Could Carry Its NASH Candidate

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124696

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel